This year’s congress of the European Society for Medical Oncology , which took place in Berlin from October 17 to 21, 2025, offered an impressive variety of topics on numerous tumor entities and therapeutic approaches. These were presented in various formats. These included interactive formats such as the “Challenge your Expert” sessions, in which the audience could ask questions, make critical comments and confront the experts with practical challenges. In the “Challenge your Expert-Session-Gynae-Cancers”, David M. Gershenson presented new therapeutic approaches for low-grade serous ovarian cancer (LGSOC). His presentation focused on the development of innovative combination therapies that go beyond the current standards of chemotherapy and hormone therapy and open up new horizons for the treatment of this rare tumor entity.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
- BRAF
- Chemotherapy + Letrozole versus Letrozole
- Combination therapy
- Hormonal therapy
- international Phase II/III study GOG 0281
- Johns Hopkins study
- KRAS
- Low grade serous ovarian carcinoma (LGSOC)
- Maintenance therapy
- MAP kinase signaling pathway mutation
- MD Anderson Cancer Center (MDACC)
- Mixed tumors LGSOC and HGSOC
- molecular precision medicine
- NRAS
You May Also Like
- Mental Health with GLP-1 RAs
Benefits of Semaglutide and Liraglutide
- Bronchiolitis obliterans
Out of shape even without popcorn
- Case study
Guillain-Barré syndrome with a fulminant course
- Suspicion of neuroborreliosis?
Detection of borrelia-specific CSF parameters provides certainty
- The Brain and the Motivation to Eat
Why is it so hard to lose weight?
- Global Recommendation, Swissmedic Approval, and SL Limitation
WHO Guidelines on GLP-1 for Obesity
- Obesity in Children and Adolescents
Gene-Environment Interactions: Polygenic or Monogenic Determinants?
- Congenital Vascular Malformations